Shilpa Medicare unveils Capecitabine 1000 MG dispersible tablet for breast cancer
With the introduction of Shilpa's new brand, "Capebel", patients will be required to just drop the tablets in 100 mL water and allow the tablets to dissolve, and then drink dissolved solution.
Karnataka: Shilpa Medicare Ltd, a Raichur (Karnataka) based pharmaceutical company has announced that the company has introduced Capecitabine 1000 MG dispersible tablet with novel technology of faster dispersion within 90 seconds.
The drug is used to treat Colorectal and Metastatic breast cancer.
"Till now Capecitabine is available in 500 mg and 150 mg tablets and the recommended doses are 3500 to 4000 mg /day divided into two doses for 14 consecutive days requiring 7 to 8 tablets to be consumed by the patients daily. This was an unmet need and remains a big issue for Cancer patients. Swallowing of 7 to 8 tablets pose a challenge in completing daily doses since most cancer patients have swallowing difficulties and hence a significant patient compliance issue," the company stated in a recent BSE filing.
With the introduction of Shilpa's new brand, "Capebel", patients will be required to just drop the tablets in 100 mL water and allow the tablets to dissolve, and then drink dissolved solution. Hence from 7 to 8 tablets a day, patients just need to drink 100 mL water twice daily with dissolved tablets in it. It is expected to change the patient's compliance and will help them continue with the correct doses with ease of drinking water.
Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India.
The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets
Read also: Shilpa Medicare bags CDSCO nod for topical hemostatic spray of Tranexamic Acid
